XML 53 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (USD $)
Series B Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income / Loss
Total
Beginning Balance - Amount at Dec. 31, 2010 $ 3,165 $ 90,342 $ 38,557,376 $ (47,229,670) $ (870,921) $ (9,449,708)
Beginning Balance - Shares at Dec. 31, 2010 3,165,225 90,342,032        
Stock-based compensation, Shares   5,585        
Stock-based compensation, Amount   6 152,736       152,742
Shares issued to consultants, Shares   30,000        
Shares issued to consultants, Amount   30 24,506       24,536
Shares issued to secured lender, Shares   4,589,360        
Shares issued to secured lender, Amount   4,589 1,657,734       1,662,323
Conversion of related party note, Shares   29,056,356        
Conversion of related party note, Amount   29,056 1,423,762       1,452,818
Beneficial conversion feature on related party note      1,732,872       1,732,872
Conversion of Series B preferred to common stock, Shares (50,000) 50,000        
Conversion of Series B preferred to common stock, Amount (50) 50            
Zymetis, Inc. merger, Shares   6,673,557        
Zymetis, Inc. merger, Amount   6,674 1,883,461       1,890,135
Other comprehensive loss            (1,372,441) (1,372,441)
Net loss         (18,296,359)    (18,296,359)
Ending Balance, Amount at Dec. 31, 2011 3,115 130,747 45,432,447 (65,526,029) (2,243,362) (22,203,082)
Ending Balance, Shares at Dec. 31, 2011 3,115,225 130,746,890        
Stock-based compensation, Shares   321,965        
Stock-based compensation, Amount   322 258,271       258,593
Shares issued to consultants, Shares   1,000,000        
Shares issued to consultants, Amount   1,000 426,466       427,466
Shares issued to secured lender, Shares   17,699,172        
Shares issued to secured lender, Amount   17,699 10,848,280       10,865,979
Issuance and exercise of warrants, Shares   1,432,667        
Issuance and exercise of warrants, Amount   1,433 1,018,167       1,019,600
Conversion of related party note, Shares   9,062,900        
Conversion of related party note, Amount   9,063 4,098,078       4,107,141
Beneficial conversion feature on related party note      884,851       884,851
Conversion of Series B preferred to common stock, Shares (17,500) 17,500        
Conversion of Series B preferred to common stock, Amount (17) 17            
Cilion, Inc. merger, Shares   20,000,000        
Cilion, Inc. merger, Amount   20,000 12,491,200       12,511,200
Other comprehensive loss            (74,531) (74,531)
Net loss         (4,282,265)    (4,282,265)
Ending Balance, Amount at Dec. 31, 2012 $ 3,098 $ 180,281 $ 75,457,760 $ (69,808,294) $ (2,317,893) $ 3,514,952
Ending Balance, Shares at Dec. 31, 2012 3,097,725 180,281,094